Cargando…

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

Antibodies targeting the PD-1/PD-L1 immune checkpoint lead to tumor regression and improved survival in several cancers. PD-L1 expression in tumors may be predictive of response to checkpoint blockade therapy. Because tissue samples might not always be available to guide therapy, we developed and ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Samit, Lesniak, Wojciech G., Gabrielson, Matthew, Lisok, Ala, Wharram, Bryan, Sysa-Shah, Polina, Azad, Babak Behnam, Pomper, Martin G., Nimmagadda, Sridhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891115/ https://www.ncbi.nlm.nih.gov/pubmed/26848870 http://dx.doi.org/10.18632/oncotarget.7143

Ejemplares similares

Development of [(18)F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
por: Lesniak, Wojciech G., et al.
Publicado: (2019)

A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts
por: Azad, Babak Behnam, et al.
Publicado: (2016)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications
por: Lesniak, Wojciech G., et al.
Publicado: (2022)

Peptide-Based (68)Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer
por: De Silva, Ravindra A., et al.
Publicado: (2018)

Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry
por: Zlitni, Aimen, et al.
Publicado: (2017)

A side-by-side evaluation of [(18)F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography
por: Narayan, Athira, et al.
Publicado: (2019)

Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
por: Nimmagadda, Sridhar
Publicado: (2020)

System-level optimization in spectroscopic photoacoustic imaging of prostate cancer
por: Wu, Yixuan, et al.
Publicado: (2022)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

Non-invasive PD-L1 quantification using [(18)F]DK222-PET imaging in cancer immunotherapy
por: Mishra, Akhilesh, et al.
Publicado: (2023)

[(64)Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma
por: Minn, Il, et al.
Publicado: (2016)

A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents
por: Chen, Ying, et al.
Publicado: (2022)

Imaging of carbonic anhydrase IX with an (111)In-labeled dual-motif inhibitor
por: Yang, Xing, et al.
Publicado: (2015)

A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)
por: Banerjee, Sangeeta Ray, et al.
Publicado: (2011)

Heterobivalent Agents Targeting PSMA and Integrin-α(v)β(3)
por: Shallal, Hassan M., et al.
Publicado: (2014)

Enhancement of Radiotherapy with Human Mesenchymal Stem Cells Containing Gold Nanoparticles
por: Pullambhatla, Mrudula, et al.
Publicado: (2020)

First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
por: Zhou, Xin, et al.
Publicado: (2022)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
por: Mishra, Akhilesh, et al.
Publicado: (2023)

Cardiac-Specific Over-Expression of Epidermal Growth Factor Receptor 2 (ErbB2) Induces Pro-Survival Pathways and Hypertrophic Cardiomyopathy in Mice
por: Sysa-Shah, Polina, et al.
Publicado: (2012)

A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen
por: Liu, Guanshu, et al.
Publicado: (2017)

Bacterial Thymidine Kinase as a Non-Invasive Imaging Reporter for Mycobacterium tuberculosis in Live Animals
por: Davis, Stephanie L., et al.
Publicado: (2009)

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
por: Ravi, Rajani, et al.
Publicado: (2018)

Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization
por: Novakova, Zora, et al.
Publicado: (2020)

(64)Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer
por: Banerjee, Sangeeta Ray, et al.
Publicado: (2014)

Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1
por: Kenn, Michael, et al.
Publicado: (2022)

Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging
por: Nimmagadda, Sridhar
Publicado: (2012)

Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
por: Krishnamachary, Balaji, et al.
Publicado: (2012)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

cis-4-[(18)F]fluoro-L-proline Molecular Imaging Experimental Liver Fibrosis
por: Cao, Qi, et al.
Publicado: (2020)

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
por: Minn, Il, et al.
Publicado: (2019)

PET imaging of soluble epoxide hydrolase in non-human primate brain with [(18)F]FNDP
por: Du, Yong, et al.
Publicado: (2020)

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
por: Hogg, Simon J., et al.
Publicado: (2017)

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
por: Hendriks, Djoke, et al.
Publicado: (2016)

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy
por: Pramanik, Dipankar, et al.
Publicado: (2012)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Tumor-Specific Imaging through Progression Elevated Gene-3 Promoter-Driven Gene Expression
por: Bhang, Hyo-eun C., et al.
Publicado: (2010)

PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
por: Jin, Jiefu, et al.
Publicado: (2022)

Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
por: Karimi, Shirin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgna3pu6tct8ka1vemb0vgd1i3